Penetration of trovafloxacin into gynecologic tissues

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 18S-22S

  Martens, Mark G ^a   Maccato, Maurizio ^b   Van Hook, Catherine ^c   Vincent, John ^d  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b Baylor University   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROVAFLOXACIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; GYNECOLOGIC INFECTION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MINIMUM INHIBITORY CONCENTRATION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL;

EID: 0032459064     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00215-3     Document Type: Article

References (22)

1. Martens MG. Ofloxacin for PID. Emerg Med. 1994;26:115-116.
2. Martens MG, Gordon S, Yarborough DR, et al. Multicenter, randomized trial of ofloxacin versus cefoxitin plus doxycycline in outpatient treatment of pelvic inflammatory disease. South Med J. 1993;86:604-610.
3. Johnson JR, Stamm WE. Diagnosis and treatment of acute urinary tract infection. Infect Dis Clin North Am. 1997;1:773-777.
4. Faro S, Martens MG, Maccato M, et al. Effectiveness of ofloxacin in the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae cervical infection. Am J Obstet Gynecol. 1991;164:1380-1383.
5. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
6. Child J, Andrews J, Boswell F, et al. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother. 1995;35:869-876.
7. Sefton AM, Maskell JP, Rafay AM, et al. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against gram-positive bacteria. J Antimicrob Chemother. 1997;39(suppl B):57-62.
8. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997;39(suppl B):43-49.
9. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994;38:2471-2476.
10. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
11. Knapp JS, Neal SW, Parekh MC, Rice RJ. In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1995;39:987-989.
12. Jones RB, Van Der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother. 1997; 39(suppl B):63-65.
13. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother. 1997;39(suppl B):75-80.
14. Teng R, Dogolo LC, Willavize SA, et al. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 1997;39(suppl B):87-92.
15. Dalvie DK, Khosla N, Vincent J. Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos. 1997;25:423-427.
16. Teng R, Tensfeldt TG, Liston TE, Foulds G. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr B. 1996;675:53-59.
17. Williams DJ, Hopkins S. Safety and tolerability of intravenous to oral treatment and single dose intravenous or oral prophylaxis with trovafloxacin. Am J Surg. 1998;176:(Supp 6A):74S-79S.
18. Martens MG, Kirshon B, Pruett K, et al. Umbilical cord and maternal serum levels of mezlocillin in term and pre-term deliveries in mothers diagnosed with chorioamnionitis. J Matern Fetal Med. 1992;1:186-191.
19. Sperling RS, Ramamurthy RS, Gibbs RS. A comparison of intrapartum versus immediate postpartum treatment of intra-amniotic infection. Obstet Gynecol 1987;70:861-865.
20. Quintiliani R, Nightingale C, Martens MG, et al. Comparative pharmacokinetics of cefotetan in patients undergoing hysterectomy and colo-rectal surgical operations. Am J Surg. 1988; 155:67-70.
21. Shapiro M, Munoz A, Tagar IB, et al. Risk factors for infection at the operative site after abdominal or vaginal hysterectomy. N Engl J Med. 1982;307:1661-1666.
22. Roy S, Koltun W, Chatwani A, et al. Treatment of acute gynecologic infections with trovafloxacin. Am J Surg. 1998;176: (Suppl 6A):67S-73S.